You are required to be logged in to access the full website
Click here if you have forgotten your username or password
Therapy Areas: Cardiovascular
Moderna Inks New Supply Agreement with Taiwan for 20m Doses of Moderna's COVID-19 Vaccine and Variant Booster Vaccine Candidate in 2022 and 15 m Doses in 2023
23 July 2021 - - US-based biotechnology company Moderna, Inc. (NASDAQ: MRNA) has inked a new supply agreement with Taiwan for 20 m doses of Moderna's COVID-19 vaccine and its updated variant booster vaccine candidate, if authorized, to begin delivery in 2022 and an additional 15m doses in 2023, the company said.
This new supply agreement is in addition to the prior agreement for 5 m doses in 2021.
Moderna's mRNA platform builds on continuous advances in basic and applied mRNA science, delivery technology and manufacturing, and has allowed the development of therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases and auto-immune diseases.
Currently, 24 development programs are underway across these therapeutic areas, with 15 programs having entered the clinic.
This new supply agreement is in addition to the prior agreement for 5 m doses in 2021.
Moderna's mRNA platform builds on continuous advances in basic and applied mRNA science, delivery technology and manufacturing, and has allowed the development of therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases and auto-immune diseases.
Currently, 24 development programs are underway across these therapeutic areas, with 15 programs having entered the clinic.
Login
Related Headlines
AstraZeneca invests USD300m to expand US manufacturing for cell therapy
Innovent Biologics announces CFO transition
Cardio Diagnostics appoints Dr Vimal Ramjee as Strategic Advisor
Acticor Biotech reports positive ACTIMIS clinical study results in Lancet Neurology Journal